ScholarIQanswers from OpenAlex & ORCID
See Cheng Yeo
ResearcherPublications, citations & collaboration network
See Cheng Yeo is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does See Cheng Yeo have?
ScholarIQindexed works
See Cheng Yeo has 52 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does See Cheng Yeo have?
ScholarIQcitation count
See Cheng Yeo has 929 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of See Cheng Yeo?
ScholarIQh-index
See Cheng Yeo has an h-index of 16 in OpenAlex.
What is the i10-index of See Cheng Yeo?
ScholarIQi10-index
See Cheng Yeo has an i10-index of 19 in OpenAlex.
What is the ORCID of See Cheng Yeo?
ScholarIQorcid
The ORCID for See Cheng Yeo is on the source record.
What is the OpenAlex record for See Cheng Yeo?
ScholarIQopenalex
The OpenAlex for See Cheng Yeo is on the source record.
What are the most-cited papers on See Cheng Yeo?
ScholarIQmost cited works
New insights into the pathogenesis of IgA nephropathy
See Cheng Yeo, Chee Kay Cheung, Jonathan Barratt
Is immunoglobulin A nephropathy different in different ethnic populations?
See Cheng Yeo, Su Mein Goh, Jonathan Barratt
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Hiddo J.L. Heerspink, Rajiv Agarwal, George L. Bakris, David Z.I. Cherney, Carolyn S.P. Lam, Brendon L. Neuen, Pantelis Sarafidis, Katherine R. Tuttle, Christoph Wanner, Meike Brinker, Sara Dizayee, Peter Kolkhof, Patrick Schloemer, Paula Vesterinen, Vlado Perkovic, for the FIND-CKD investigators, Julio Bittar, Cesar Javier Zaidman, Natalia Cluigt, Miguel Hominal, Paola Aguerre, Fernando Halac, Elizabeth Gelersztein, M. Arriola, Rafaël Maldonado, Mariano Chahin, David Packham, Darren J. Lee, Eugenia Pedagogos, Celine Foote, Sunil V. Badve, Carmel M. Hawley, Jenny Chen, Nicholas A. Gray, Marijn M. Speeckaert, Laura Labriola, Peter Doubel, Bart Maes, Kathleen Claes, Bernard Dubois, Irena Dimitrova, Tsvetelina Vutova, Stefan Ilchev, Svetla Stamova, Yordanka Ivanova, А М Васильева, Xiangmei Chen, Shuifu Tang, Xudong Xu, Bi‐Cheng Liu, Weiming He, Yani He, Fang Liu, Caili Wang, Lianhua Chen, Jianying Niu, Deguang Wang, Ping Luo, Yuou Xia, Gengru Jiang, Qun Luo, Fang Wang, Menghua Chen, Hongli Lin, Rui Yan, Yinan Li, Qinkai Chen, Junwu Dong, Fei Xiong, Haibo Long, Hong Cheng, Yuehong Li, Juan Du, Fanna Liu, Qingping Chen, Wanhong Lu, Chaosheng Chen, Jianqin Wang, Lei Liu, Min Yang, Gang Long, Yongjun Shi, Wenge Li, Xiangdong Yang, Aicheng Yang, Jianfei Li, Xiaoyan Meng, Martin Prázný, Lucie Hornova, Petr Bucek, Mária Majerníková, Jan Wirth, Jitka Řehořová, Mads Hornum, Jesper Nørgaard Bech, Morten Lindhardt, Ditte Hansen, Line Mortensen, Claus Bogh Juhl, Ioannis Boletis
Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review
See Cheng Yeo, Hankun Wang, Gary Yee Ang, Chee Kong Lim, Xin Yi Ooi
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial
Jonathan Barratt, Adrian Liew, See Cheng Yeo, Anders Fernström, Sean J. Barbour, C. John Sperati, Russell Villanueva, Ming‐Ju Wu, Dazhe Wang, Anna Borodovsky, Prajakta Badri, Elena Yureneva, Ishir Bhan, Daniel Cattran, on behalf of the Cemdisiran Phase 2 Study Investigators and Collaborators